Titanovo Logo
Back to Cell Types

NALM-6Homo sapiens (Human)Cancer cell line

Also known as: Nalm-6, NALM 6, Nalm 6, NALM6, Nalm6, NALM-6-M1

🤖 AI SummaryBased on 8 publications

Quick Overview

Human B-cell precursor acute lymphoblastic leukemia cell line

Detailed Summary

NALM-6 is a human B-cell precursor acute lymphoblastic leukemia (B-ALL) cell line established from the blood of a 19-year-old male patient with non-T, non-B ALL in relapse. The cell line exhibits characteristics of pre-B cell phenotype, with cytoplasmic immunoglobulin (Ig) expression and lack of surface Ig. It shows a deletion in the long arm of chromosome 5 (5q) and a marker Y chromosome. NALM-6 has been used in studies related to leukemia research, including investigations of genetic alterations, copy number abnormalities, and molecular mechanisms of leukemogenesis. It is also part of the Cancer Cell Line Encyclopedia (CCLE) and has been characterized for HLA typing, gene expression, and neo-epitopes.

Research Applications

Leukemia researchGenetic and molecular characterizationDrug sensitivity studiesCopy number abnormality analysis

Key Characteristics

Pre-B cell phenotypeCytoplasmic immunoglobulin expressionChromosome 5q deletionHLA typing and neo-epitope analysis
Generated on 6/14/2025

Basic Information

Database IDCVCL_0092
SpeciesHomo sapiens (Human)
Tissue SourcePeripheral blood[UBERON:UBERON_0000178]

Donor Information

Age19
Age CategoryAdult
SexMale
Subtype FeaturesDUX4   

Disease Information

DiseaseAdult B acute lymphoblastic leukemia
LineageLymphoid
SubtypeB-Lymphoblastic Leukemia/Lymphoma
OncoTree CodeBLL

DepMap Information

Source TypeDSMZ
Source IDACH-000938_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
Gene fusionDUX4IGH-DUX4-The translocation occurs in the silenced IGH allelefrom parent cell line Nalm-6-MSH+/TK+/-
MutationSimpleEGFRp.Arg1068Ter (c.3202C>T)Heterozygous-from parent cell line Nalm-6-MSH+/TK+/-
MutationSimpleNRASp.Ala146Thr (c.436G>A)Unspecified-Wistar
MutationSimpleRARAp.Gln45Ter (c.133C>T)Heterozygous-from parent cell line Nalm-6-MSH+/TK+/-

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
12
D13S317
8,9,11,12
D16S539
9,10,11
D18S51
11,12,14,15
D19S433
12,13,15
D21S11
28,29
D2S1338
17,24
D2S441
10,14
D3S1358
15,16,17
D5S818
10,11,12
D6S1043
11
D7S820
8,12
D8S1179
11,13,14
FGA
21,22
Penta D
8,14
Penta E
11
TH01
8
TPOX
8,10
vWA
15,16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.

Lehtio J., Vesterlund M., Jafari R.

Nat. Commun. 13:1691.1-1691.19(2022).

DOIPubMedPMC

Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.

Minegishi M., Iwamoto S., Sugita K., Inukai T.

J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).

DOIPubMed

Characterization of a novel glucocorticoid-resistant human B-cell acute lymphoblastic leukemia cell line, with AMPK, mTOR and fatty acid synthesis pathway inhibition.

Li Y.-Y., Zuo C., Gu L.

Cancer Cell Int. 21:623.1-623.14(2021).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

Long-read sequencing unveils IGH-DUX4 translocation into the silenced IGH allele in B-cell acute lymphoblastic leukemia.

Zhang J.-H.

Nat. Commun. 10:2789.1-2789.10(2019).

DOIPubMedPMC

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOIPubMedPMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOIPubMedPMC

Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.

Sugita K., Hosoi H.

Int. J. Hematol. 108:312-318(2018).

DOIPubMed

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Characterization of a leukemic cell line of the pre-B phenotype.";

Kubonishi I., Kersey J.H.

Int. J. Cancer 23:174-180(1979).

DOIPubMed

Use of stimulating capacity of mixed lymphocyte reaction (MLR-S) as a possible marker for the cell-origin of null-cell acute lymphoblastic leukaemia.

Han T., Minowada J.

Immunology 35:333-339(1978).

PubMedPMC

Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.

Nakano A., Harada T., Morikawa S., Kato Y.

Acta Pathol. Jpn. 40:107-115(1990).

DOIPubMed

Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines.

Kornacki M., Ritz J., Blattler W.A.

J. Immunol. 136:320-325(1986).

DOIPubMed

Establishment of ascitic tumor of human pre-B acute lymphoblastic leukemia in nonconditioned nude mice.

Luo Y., Hara H., Haruta Y., Seon B.K.

Cancer Res. 49:706-710(1989).

PubMed

Differential expression of HLA-DR, -DQ, and -DP antigens on malignant B cells.

Pesando J.M., Graf L.

J. Immunol. 136:4311-4318(1986).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cell lines -- 1. carboxylic esterase.

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:209-229(1985).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cell lines -- III. Beta-hexosaminidase (E.C. 3.2.1.30).

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:549-559(1985).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:537-548(1985).

DOIPubMed

Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.

Nakamura H., Amakawa R., Ohno H.

Leukemia 10:1592-1603(1996).

PubMed

Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.

Janssen J.W.G., Drexler H.G.

Leukemia 11:441-447(1997).

DOIPubMed

Frameshift mutations of the hMSH6 gene in human leukemia cell lines.

Hirai H.

Jpn. J. Cancer Res. 89:33-39(1998).

DOIPubMedPMC

Establishment and characterization of human B cell precursor-leukemia cell lines.

Matsuo Y., Drexler H.G.

Leuk. Res. 22:567-579(1998).

DOIPubMed

Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.

Aizawa Y., Ueda R., Seto M.

Jpn. J. Cancer Res. 89:712-718(1998).

DOIPubMedPMC

EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1.

Fu X.-Y., McGrath S., Pasillas M., Nakazawa S., Kamps M.P.

Oncogene 18:4920-4929(1999).

DOIPubMed

Efficient DNA fingerprinting method for the identification of cross-culture contamination of cell lines.

Matsuo Y., Nishizaki C., Drexler H.G.

Hum. Cell 12:149-154(1999).

PubMed

Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Leuk. Res. 24:255-262(2000).

DOIPubMed

Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.

Gaulton G.N., Ratajczak M.Z.

Leukemia 14:1821-1832(2000).

DOIPubMed

Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Leuk. Res. 25:275-278(2001).

DOIPubMed

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

DOIPubMedPMC

N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.

O'Donnell P.H., Guo W.-X., Reynolds C.P., Maurer B.J.

Leukemia 16:902-910(2002).

DOIPubMed

Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.

Fioretos T.

Leukemia 19:1042-1050(2005).

DOIPubMed

The human pre-B cell line Nalm-6 is highly proficient in gene targeting by homologous recombination.

Miyagawa K., Koyama H.

DNA Cell Biol. 25:19-24(2006).

DOIPubMed

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.

Leukemia 20:471-476(2006).

DOIPubMed

Recurrent KRAS codon 146 mutations in human colorectal cancer.";

Yuen S.T., Leung S.Y., Stratton M.R., Futreal P.A.

Cancer Biol. Ther. 5:928-932(2006).

DOIPubMedPMC

Gene targeting using the human Nalm-6 pre-B cell line.";

Adachi N., Nishijima H., Shibahara K.-i.

Biosci. Trends 2:169-180(2008).

PubMed

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.

Tada M., Moriuchi T., Sugita K.

Am. J. Hematol. 85:535-537(2010).

DOIPubMedPMC

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Reynolds C.P.

Pediatr. Blood Cancer 56:239-249(2011).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Restoration of mismatch repair functions in human cell line Nalm-6, which has high efficiency for gene targeting.

Suzuki T., Ukai A., Honma M., Adachi N., Nohmi T.

PLoS ONE 8:E61189-E61189(2013).

DOIPubMedPMC

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOIPubMedPMC

Web Resources

thermofisher.comcccells.orgpptpinvitro.orgtcpaportal.org